비교리스트

 카트 문의
시장보고서
상품코드
1667899

접합 백신 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측, 제품 유형별, 적응 질환별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

Conjugate Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Disease Indication, By End-User, By Region and Competition, 2020-2030F
발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 184 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

접합 백신 세계 시장 규모는 2024년 196억 9,000만 달러, 2030년에는 341억 달러에 달할 것으로 예상되며, 연평균 9.56%의 성장률을 보일 것으로 예측됩니다.

이러한 시장 확대의 배경에는 예방의료에 대한 인식이 높아진 것이 큰 역할을 하고 있습니다. 세계 각국의 정부와 의료기관은 폐렴구균, 인플루엔자 b형(Hib), 수막염균 감염과 같은 감염성 질환의 확산을 막기 위해 예방접종률 향상에 주력하고 있습니다. 전 세계 의료비 지출 증가와 선진국과 개발도상국 모두에서 백신 접종 프로그램의 우선순위가 높아지면서 시장 개척에 유리한 환경이 조성되고 있습니다. 또한, 하나의 제형으로 여러 병원체를 표적으로 하는 백신에 대한 수요가 증가함에 따라 비용 효율적이면서 종합적인 방어력을 제공하는 다중접합백신 개발에 박차를 가하고 있습니다. 특히 영유아와 노인과 같은 사회적 약자들 사이에서 생명을 위협하는 질병을 예방하는 백신의 역할에 대한 인식이 높아진 것도 시장 확대에 기여하고 있습니다.

시장 개요
예측 기간 2026-2030년
시장 규모 : 2024년 196억 9,000만 달러
시장 규모 : 2030년 341억 달러
CAGR(2025-2030년) 9.56%
급성장 부문 병원 클리닉
최대 시장 북미

시장 성장 촉진요인

예방의료에 대한 인식 제고

주요 시장 과제

높은 제조 비용

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 접합 백신 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품 유형별(단가 결합 백신, 다가 결합 백신)
    • 적응 질환별(폐렴구균, 인플루엔자, 수막염균, 장티푸스)
    • 최종사용자별(병원 클리닉, 외래 진료 센터, 기타)
    • 지역별
    • 기업별(2024년)
  • 시장 맵
    • 제품 유형별
    • 적응 질환별
    • 최종사용자별
    • 지역별

제5장 아시아태평양의 접합 백신 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품 유형별
    • 적응 질환별
    • 최종사용자별
    • 국가별
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 호주
    • 일본
    • 한국

제6장 유럽의 접합 백신 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
  • 유럽 : 국가별 분석
    • 독일
    • 스페인
    • 이탈리아
    • 영국

제7장 북미의 접합 백신 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
  • 북미 : 국가별 분석
    • 멕시코
    • 캐나다

제8장 남미의 접합 백신 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
  • 남미 : 국가별 분석
    • 아르헨티나
    • 콜롬비아

제9장 중동 및 아프리카의 접합 백신 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
  • 중동 및 아프리카 : 국가별 분석
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이집트

제10장 시장 역학

  • 성장 촉진요인
  • 과제

제11장 시장 동향과 발전

  • 제품 출시
  • 인수합병(M&A)

제12장 세계의 접합 백신 시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

  • 산업내 경쟁
  • 신규 참여 가능성
  • 공급업체의 힘
  • 고객의 힘
  • 대체품의 위협

제14장 경쟁 구도

  • Sanofi S.A
  • Pfizer Inc.
  • Merck & Co. Inc.
  • GlaxoSmithKline plc
  • Bharat BIoTech International Limited
  • Serum Institute of India Pvt. Ltd
  • Biological E. Limited
  • Bavarian Nordic A/S
  • CSL Limited
  • Novartis AG

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH 25.04.04

The Global Conjugate Vaccine Market was valued at USD 19.69 billion in 2024 and is projected to reach USD 34.10 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.56%. This significant market expansion is driven by the increasing recognition of preventive healthcare. Governments and healthcare organizations globally are focused on improving immunization coverage to reduce the prevalence of infectious diseases such as pneumococcal infections, Haemophilus influenzae type b (Hib), and meningococcal diseases. Rising global healthcare spending and the prioritization of vaccination programs in both developed and developing nations have created a favorable environment for market growth. Additionally, the demand for vaccines targeting multiple pathogens in a single formulation has spurred the development of multivalent conjugate vaccines, which offer comprehensive protection while enhancing cost-effectiveness. The growing awareness of vaccines' role in preventing life-threatening diseases, particularly among vulnerable populations like infants and the elderly, has further contributed to market expansion.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 19.69 Billion
Market Size 2030USD 34.10 Billion
CAGR 2025-20309.56%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Key Market Drivers

Increasing Awareness of Preventive Healthcare

The growing awareness of preventive healthcare is a crucial factor driving the expansion of the Global Conjugate Vaccine Market. In recent years, there has been a notable shift from a curative to a preventive healthcare approach. This shift is supported by the understanding that preventing diseases through vaccination is more cost-effective and less burdensome on individuals and healthcare systems than treating illnesses after they occur.

Key Market Challenges

High Manufacturing Costs

The manufacturing complexity of conjugate vaccines arises from their unique composition. These vaccines combine a weak antigen with a potent one to generate a stronger immune response. Achieving this requires advanced biotechnological techniques and strict quality control throughout production. Additionally, rigorous regulatory requirements further contribute to the overall production cost. High manufacturing costs limit the accessibility of conjugate vaccines, especially in low- and middle-income countries, where budget constraints often hinder vaccine procurement and affordability. Even in developed countries with robust healthcare systems, the high cost of conjugate vaccines can pose challenges, potentially deterring healthcare providers and individuals from prioritizing these vaccines, despite their proven efficacy.

Key Market Players

  • Sanofi S.A.
  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Bharat Biotech International Limited
  • Serum Institute of India Pvt. Ltd
  • Biological E. Limited
  • Bavarian Nordic A/S
  • CSL Limited
  • Novartis AG

Report Scope

This report segments the Global Conjugate Vaccine Market by the following categories, along with detailed insights into industry trends:

By Product Type:

  • Monovalent Conjugate Vaccines
  • Multivalent Conjugate Vaccines

By Disease Indication:

  • Pneumococcal
  • Influenza
  • Meningococcal
  • Typhoid

By End-User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

By Region:

  • North America:
  • United States
  • Canada
  • Mexico
  • Europe:
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific:
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America:
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa:
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

The competitive landscape includes detailed profiles of the major companies operating in the Global Conjugate Vaccine Market.

Available Customizations

TechSci Research offers customizations for the Global Conjugate Vaccine Market report to suit specific business needs. Customization options include:

  • Detailed analysis and profiling of up to five additional market players.

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Conjugate Vaccine Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Product Type (Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine)
    • 4.2.2. By Disease Indication (Pneumococcal, Influenza, Meningococcal, Typhoid)
    • 4.2.3. By End-User (Hospitals & Clinics, Ambulatory care Centers, Others)
    • 4.2.4. By Region
    • 4.2.5. By Company (2024)
  • 4.3. Market Map
    • 4.3.1. By Product Type
    • 4.3.2. By Disease Indication
    • 4.3.3. By End-User
    • 4.3.4. By Region

5. Asia Pacific Conjugate Vaccine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type
    • 5.2.2. By Disease Indication
    • 5.2.3. By End-User
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Conjugate Vaccine Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Product Type
        • 5.3.1.2.2. By Disease Indication
        • 5.3.1.2.3. By End-User
    • 5.3.2. India Conjugate Vaccine Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Product Type
        • 5.3.2.2.2. By Disease Indication
        • 5.3.2.2.3. By End-User
    • 5.3.3. Australia Conjugate Vaccine Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Product Type
        • 5.3.3.2.2. By Disease Indication
        • 5.3.3.2.3. By End-User
    • 5.3.4. Japan Conjugate Vaccine Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Product Type
        • 5.3.4.2.2. By Disease Indication
        • 5.3.4.2.3. By End-User
    • 5.3.5. South Korea Conjugate Vaccine Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Product Type
        • 5.3.5.2.2. By Disease Indication
        • 5.3.5.2.3. By End-User

6. Europe Conjugate Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Disease Indication
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Conjugate Vaccine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Disease Indication
        • 6.3.1.2.3. By End-User
    • 6.3.2. Germany Conjugate Vaccine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Disease Indication
        • 6.3.2.2.3. By End-User
    • 6.3.3. Spain Conjugate Vaccine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Disease Indication
        • 6.3.3.2.3. By End-User
    • 6.3.4. Italy Conjugate Vaccine Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Product Type
        • 6.3.4.2.2. By Disease Indication
        • 6.3.4.2.3. By End-User
    • 6.3.5. United Kingdom Conjugate Vaccine Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Product Type
        • 6.3.5.2.2. By Disease Indication
        • 6.3.5.2.3. By End-User

7. North America Conjugate Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Disease Indication
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Conjugate Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Disease Indication
        • 7.3.1.2.3. By End-User
    • 7.3.2. Mexico Conjugate Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Disease Indication
        • 7.3.2.2.3. By End-User
    • 7.3.3. Canada Conjugate Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Disease Indication
        • 7.3.3.2.3. By End-User

8. South America Conjugate Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Disease Indication
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Conjugate Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Disease Indication
        • 8.3.1.2.3. By End-User
    • 8.3.2. Argentina Conjugate Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Disease Indication
        • 8.3.2.2.3. By End-User
    • 8.3.3. Colombia Conjugate Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Disease Indication
        • 8.3.3.2.3. By End-User

9. Middle East and Africa Conjugate Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Disease Indication
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Conjugate Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Disease Indication
        • 9.3.1.2.3. By End-User
    • 9.3.2. Saudi Arabia Conjugate Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Disease Indication
        • 9.3.2.2.3. By End-User
    • 9.3.3. UAE Conjugate Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Disease Indication
        • 9.3.3.2.3. By End-User
    • 9.3.4. Egypt Conjugate Vaccine Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Product Type
        • 9.3.4.2.2. By Disease Indication
        • 9.3.4.2.3. By End-User

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Conjugate Vaccine Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Sanofi S.A
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Pfizer Inc.
  • 14.3. Merck & Co. Inc.
  • 14.4. GlaxoSmithKline plc
  • 14.5. Bharat Biotech International Limited
  • 14.6. Serum Institute of India Pvt. Ltd
  • 14.7. Biological E. Limited
  • 14.8. Bavarian Nordic A/S
  • 14.9. CSL Limited
  • 14.10. Novartis AG

15. Strategic Recommendations

16. About Us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제